Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 32766473 | HLA-B*54 | nafld | Japanese | NA | rs2076529 | unclassified | |
| next-generation sequence-based typing of hla in 5,649 members of the general population replicated the significant difference of hla-b allele distribution and the significant increase of the hla-b*54:01 allele in whole nafld. | |||||||
| 32766473 | HLA-B*54 | nafld | Japanese | NA | rs2076529 | lack_of_evidence | |
| veillonellaceae was increased but verrucomicrobia was decreased in rs2076529 minor allele and hla-b*54:01 allele carriers as in nafld. | |||||||
| 32766473 | HLA (HLA) | nafld | Japanese | NA | rs2076529 | unclassified | |
| conclusion: hla was identified as a novel locus associated with nafld susceptibility, which might be affected by the alteration of gut microbiota. | |||||||
| 26201788 | HLA-DR (HLA-DR) | nafld | NA | NA | NA | negation | |
| although the frequency of mo-dcs in nafld patients was similar to that of healthy controls, there was no upregulation in levels of hla-dr, cd83, cd80 and cd86 on their surface in response to lps stimulation ex vivo. | |||||||
| 27141367 | HLA (HLA) | triple-negative breast cancer | NA | NA | NA | unclassified | |
| we investigated macrophage activation in response to co-culture with several breast cancer cell lines (t47d, mcf-7, bt-474, skbr-3, cal-51 and mda-mb-231) and found that high granulocyte colony-stimulating factor (g-csf) secretion by the triple-negative breast cancer (tnbc) cell line mda-mb-231 gave rise to immunosuppressive hla-drlo macrophages that promoted migration of breast cancer cells via secretion of tgf-a. | |||||||
| 32071118 | HLA-A*02 | triple-negative breast cancer | NA | trastuzumab | NA | unclassified | |
| eligible patients were hla-a2, a3, a24, and/or a26+, and had her2 ihc 1+/2+, fish nonamplified breast cancer, that was node positive and/or hormone receptor-negative [triple-negative breast cancer (tnbc)]. | |||||||
| 32071118 | HLA-A*24 | triple-negative breast cancer | NA | trastuzumab | NA | unclassified | |
| eligible patients were hla-a2, a3, a24, and/or a26+, and had her2 ihc 1+/2+, fish nonamplified breast cancer, that was node positive and/or hormone receptor-negative [triple-negative breast cancer (tnbc)]. | |||||||
| 32071118 | HLA-A*26 | triple-negative breast cancer | NA | trastuzumab | NA | unclassified | |
| eligible patients were hla-a2, a3, a24, and/or a26+, and had her2 ihc 1+/2+, fish nonamplified breast cancer, that was node positive and/or hormone receptor-negative [triple-negative breast cancer (tnbc)]. | |||||||
| 25381056 | DR-DQ (HAPLOTYPE) | b virus infections | NA | NA | NA | negation | |
| t-cell responses did not correlate clearly to the individual hla-dr-dq phenotype or the history of past coxsackie b virus infections of the donors. | |||||||
| 25383971 | HLA-DRB1 (HLA-DRB1) | enteric fever | NA | NA | rs7765379 | unclassified | |
| variation at hla-drb1 is associated with resistance to enteric fever. | |||||||
Copyright 2024